^
BIOMARKER:

HRAS G12D

i
Other names: HRAS, HRAS1, Harvey rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
10ms
Genetically and clinically annotated HNSCC PDXs could be useful preclinical tools for evaluating biomarkers, therapeutic targets, and new drug discovery.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CCND1 (Cyclin D1)
|
TP53 mutation • PIK3CA mutation • PIK3CA H1047R • HRAS mutation • CCND1 amplification • PIK3CA amplification • NRAS G12 • HRAS G12D
over1year
Pharmacodynamic analyses support the antitumor and immune effects of sitravatinib and nivolumab in OCC. Immune pathological response assessment and transcriptomics are on-going. Research Funding: Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Pharmaceutical/Biotech Company
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • AXL (AXL Receptor Tyrosine Kinase) • VEGFA (Vascular endothelial growth factor A) • MERTK (MER Proto-Oncogene, Tyrosine Kinase)
|
HRAS mutation • BLM mutation • HRAS G12D
|
Opdivo (nivolumab) • sitravatinib (MGCD516)